Spirax Group Reports Steady H1 2025 Results and Reiterates Full-Year Guidance

Steady as She Goes: Spirax Navigates Macro Headwinds

Spirax Group’s H1 2025 results land with reassuring predictability – a welcome sight amidst choppy economic waters. While statutory figures show expected pressure, the underlying story is one of resilient organic growth and disciplined execution. The real headline? Full-year guidance stands firm, suggesting management’s confidence isn’t just bluster.

The Raw Numbers: Look Beyond the Headlines

At first glance, the reported figures might raise eyebrows:

• Revenue: £822.2m (down 1% year-on-year)
• Statutory Operating Profit: £106.8m (down 27%)
• Statutory EPS: 85.0p (down 31%)

But this is where the ‘adjusted’ lens becomes crucial. Strip out significant one-off restructuring costs (£34.6m) and hefty currency headwinds (a 7% drag on adjusted operating profit), and the engine room looks healthier:

• Organic Revenue Growth: +3% (comfortably ahead of global industrial production growth of 2.5%)
• Organic Adjusted Operating Profit Growth: +7%
• Organic Adjusted Operating Margin: Up 70 basis points to 19.3%
• Adjusted Cash Conversion: Jumped to 61% (from 53%) – a real win on working capital discipline
• Interim Dividend: Up 3% to 48.9p – signalling confidence in cash flow

The message is clear: operational performance is holding up well against a challenging macro backdrop. That currency hit was anticipated and flagged back in May – no surprises here.

Segment Deep Dive: Divergent Paths, Shared Resilience

Breaking down Spirax’s three core businesses reveals fascinating dynamics:

1. Steam Thermal Solutions (STS): Playing Defence Well

Revenue (£414.2m) was flat organically – a decent result given the -4% reported figure. The drag came from expected weakness in large projects, particularly in China and Korea. Crucially:

• Excluding those large projects? Organic growth hit 3%.
• MRO and solution-sales shone, especially in China (double-digit growth).
• Adjusted operating profit grew 3% organically, with margin up 60bps to 23.4% – efficiency wins funding future growth bets.

STS is successfully pivoting towards more resilient demand streams.

2. Electric Thermal Solutions (ETS): The Star Performer

This segment is firing on all cylinders:

• Organic Revenue Growth: +10% (£212.3m)
• Organic Adjusted Operating Profit Growth: +12% (£31.8m)
• Driven by robust demand across Process Heating, Equipment Heating, and Heat Trace, plus a major datacentre contract win.
• Recovering Semicon demand provided a welcome tailwind.

Operational improvements are translating into tangible results here.

3. Watson-Marlow Fluid Tech (WMFTS): Biopharm Orders Signal H2 Surge

A solid if unspectacular H1 (Revenue: £195.7m, +2% organic) masks exciting momentum:

• Process Industries growth significantly outpaced IP.
• The crucial signal: Biopharm order intake surged over 10%.
• For the first time since 2021 peak COVID demand, orders exceed sales – priming WMFTS for stronger H2 revenue growth.
• Adjusted operating profit jumped 12% organically, with margin expanding 240bps to 25.9%.

WMFTS looks set to shift gears later this year.

Restructuring Bite & Cash Flow Muscle

That hefty £34.6m restructuring charge is the main culprit behind the ugly statutory profit drop. It’s part of a significant efficiency drive aiming for £35m annualised savings (half expected in H2 2025). The pain is real but purposeful – funding reinvestment in growth initiatives like digital and decarbonisation.

More impressively, cash generation strengthened markedly. Adjusted cash conversion at 61% reflects excellent working capital management and capital discipline. Net debt reduced to £658m (leverage: 1.8x), providing ample headroom. The 3% dividend hike feels well-supported.

Outlook: Steady Hand on the Tiller

Management isn’t blinking. Despite CHR Economics revising down H2 global IP forecasts to 2.0% (1.7% ex-China), Spirax reiterates its full-year guidance:

• Organic revenue growth consistent with 2024 (and ahead of IP).
• Adjusted operating profit margin ahead of the currency-adjusted 2024 baseline (19.4%).
• Mid-single-digit organic growth in adjusted operating profit.
• Cash conversion expected to improve further above 80%.

Confidence stems from strong order books (especially in STS and WMFTS), improving demand in key end-markets like Biopharm and Semicon, and the phasing of restructuring benefits. Expect H2 sales growth to accelerate.

The Verdict: Engineering Efficiency, Delivering Certainty

Spirax’s H1 is a masterclass in navigating known headwinds. Currency and restructuring impacts were flagged and delivered as expected, but crucially, the core operational engine – organic growth and margin expansion – performed well. The reiteration of full-year guidance in a murky macro environment is perhaps the most bullish signal. It suggests the “Together for Growth” strategy isn’t just a slogan; it’s delivering tangible operational resilience and funding future growth vectors like electrification and decarbonisation.

For investors seeking steady, engineering-led value in the industrials space, Spirax continues to offer a compelling, if rarely flashy, proposition. The 3% dividend hike is the cherry on top of a fundamentally solid half-year performance. Keep an eye on that WMFTS order book and ETS momentum – they could be the drivers of upside surprises later this year.